<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Research &amp; projects - Leiomyosarcoma Research UK</title>
	<atom:link href="https://lmsruk.org/category/research-projects/feed/" rel="self" type="application/rss+xml" />
	<link>https://lmsruk.org/category/research-projects/</link>
	<description>Funding better outcomes for everyone affected by LMS</description>
	<lastBuildDate>Mon, 02 Nov 2026 09:20:57 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.5</generator>

<image>
	<url>https://lmsruk.org/wp-content/uploads/2026/04/cropped-flower-modified-32x32.png</url>
	<title>Research &amp; projects - Leiomyosarcoma Research UK</title>
	<link>https://lmsruk.org/category/research-projects/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Leiomyosarcoma (LMS) Pathfinder Network</title>
		<link>https://lmsruk.org/research-projects/leiomyosarcoma-lms-pathfinder-network/</link>
					<comments>https://lmsruk.org/research-projects/leiomyosarcoma-lms-pathfinder-network/#respond</comments>
		
		<dc:creator><![CDATA[jack]]></dc:creator>
		<pubDate>Wed, 06 May 2026 06:42:39 +0000</pubDate>
				<category><![CDATA[Engagement]]></category>
		<category><![CDATA[Research]]></category>
		<category><![CDATA[Research & projects]]></category>
		<guid isPermaLink="false">https://lmsrukdev.4pplecore.dev/?p=272</guid>

					<description><![CDATA[<p>Chaired by Professor Ian Judson, the LMS Pathfinder Network brings together healthcare professionals from across the UK with an interest in sarcoma. Members include clinicians, biological researchers, nurse practitioners, data scientists, and other specialists. The aim of the network is to promote the sharing of best practice, foster closer collaboration, and support the development of [&#8230;]</p>
<p>The post <a href="https://lmsruk.org/research-projects/leiomyosarcoma-lms-pathfinder-network/">Leiomyosarcoma (LMS) Pathfinder Network</a> appeared first on <a href="https://lmsruk.org">Leiomyosarcoma Research UK</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">Chaired by Professor Ian Judson, the LMS Pathfinder Network brings together healthcare professionals from across the UK with an interest in sarcoma. Members include clinicians, biological researchers, nurse practitioners, data scientists, and other specialists. The aim of the network is to promote the sharing of best practice, foster closer collaboration, and support the development of novel and disruptive research and innovations to improve outcomes for patients with sarcoma.</p>



<p class="wp-block-paragraph">The network focuses initially on leiomyosarcoma as a &#8216;pathfinder&#8217; subtype, using it to pilot approaches and programmes that may later be explored or applied to other soft tissue sarcoma subtypes.</p>



<p class="wp-block-paragraph">Currently, the network includes representation from all UK Soft Tissue Sarcoma Centres of Excellence, alongside growing engagement with regional hospitals that have a clinical or research interest in sarcoma. In addition, there has been broader collaboration with gynaecology and gynaecological oncology colleagues, particularly those with an interest in uterine sarcomas, as part of the projects currently being supported.</p>
<p>The post <a href="https://lmsruk.org/research-projects/leiomyosarcoma-lms-pathfinder-network/">Leiomyosarcoma (LMS) Pathfinder Network</a> appeared first on <a href="https://lmsruk.org">Leiomyosarcoma Research UK</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://lmsruk.org/research-projects/leiomyosarcoma-lms-pathfinder-network/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>L-UteCIN Clinical Trial: Adjuvant chemotherapy in patients with CINSARC high-risk localised resected uterine leiomyosarcoma</title>
		<link>https://lmsruk.org/research-projects/l-utecin-clinical-trial-interest-of-adjuvant-chemotherapy-in-patients-with-cinsarc-high-risk-localised-resected-uterine-leiomyosarcoma/</link>
					<comments>https://lmsruk.org/research-projects/l-utecin-clinical-trial-interest-of-adjuvant-chemotherapy-in-patients-with-cinsarc-high-risk-localised-resected-uterine-leiomyosarcoma/#respond</comments>
		
		<dc:creator><![CDATA[jack]]></dc:creator>
		<pubDate>Wed, 06 May 2026 06:39:55 +0000</pubDate>
				<category><![CDATA[Research & projects]]></category>
		<category><![CDATA[Trials]]></category>
		<guid isPermaLink="false">https://lmsrukdev.4pplecore.dev/?p=263</guid>

					<description><![CDATA[<p>Prof. Robin Jones (The Royal Marsden Hospital Trust, London).</p>
<p>The post <a href="https://lmsruk.org/research-projects/l-utecin-clinical-trial-interest-of-adjuvant-chemotherapy-in-patients-with-cinsarc-high-risk-localised-resected-uterine-leiomyosarcoma/">L-UteCIN Clinical Trial: Adjuvant chemotherapy in patients with CINSARC high-risk localised resected uterine leiomyosarcoma</a> appeared first on <a href="https://lmsruk.org">Leiomyosarcoma Research UK</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">We are supporting the development of an important new clinical trial investigating adjuvant chemotherapy for people diagnosed with uterine leiomyosarcoma (uLMS), a rare and aggressive form of cancer. This work reflects our commitment to improving treatment options and outcomes for patients affected by uLMS, where progress has historically been limited.</p>



<p class="wp-block-paragraph">The trial is being run in France and the UK and will be led by Professor Robin Jones in the UK. The study will focus on the use of combination doxorubicin-trabectedin chemotherapy following surgery. This chemotherapy regimen has shown promise in other uLMS settings, and the trial aims to explore whether its earlier use can bring benefits for patients after their primary cancer has been removed.</p>



<p class="wp-block-paragraph">At present, the standard approach for uLMS patients whose cancer is localised at diagnosis is surgical removal followed by close monitoring. However, recurrence rates remain high, and there is a lack of evidence to guide the use of additional treatment after surgery. This trial seeks to address that gap by evaluating chemotherapy in the adjuvant (post-surgical) setting.</p>



<p class="wp-block-paragraph">By contributing towards this study, we are helping to advance research that could fundamentally change how uLMS is treated in the UK. The trial will investigate whether adjuvant chemotherapy can reduce recurrence risk, improve survival, and ultimately lead to better long-term outcomes for patients considered at higher risk.</p>



<p class="wp-block-paragraph">Preparatory work for the trial is currently underway. This includes trial design finalisation, regulatory approvals, and coordination with participating hospitals. We will share further details, including eligibility criteria and timelines for recruitment, as soon as they become available.</p>



<p class="wp-block-paragraph">The trial will be coordinated by The Royal Marsden, ensuring robust clinical oversight and adherence to the highest research standards. The leadership and expertise involved will help to ensure that the findings are reliable, meaningful, and applicable across the UK healthcare system.</p>



<p class="wp-block-paragraph">Wherever possible, it is hoped that the trial will be opened to centres across the UK, enabling broad participation and improving access for eligible patients. A national approach will also strengthen recruitment and help ensure that the results are representative and widely applicable.</p>



<p class="wp-block-paragraph">If successful, this study could provide much-needed evidence to support the use of adjuvant chemotherapy in uLMS, influencing future clinical guidelines and offering new hope to patients facing this challenging diagnosis.</p>
<p>The post <a href="https://lmsruk.org/research-projects/l-utecin-clinical-trial-interest-of-adjuvant-chemotherapy-in-patients-with-cinsarc-high-risk-localised-resected-uterine-leiomyosarcoma/">L-UteCIN Clinical Trial: Adjuvant chemotherapy in patients with CINSARC high-risk localised resected uterine leiomyosarcoma</a> appeared first on <a href="https://lmsruk.org">Leiomyosarcoma Research UK</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://lmsruk.org/research-projects/l-utecin-clinical-trial-interest-of-adjuvant-chemotherapy-in-patients-with-cinsarc-high-risk-localised-resected-uterine-leiomyosarcoma/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Practice and Results in the Investigation and Management of Uterine Sarcomas (PRIMUS) Study</title>
		<link>https://lmsruk.org/research-projects/practice-and-results-in-the-investigation-and-management-of-uterine-sarcomas-primus-study/</link>
					<comments>https://lmsruk.org/research-projects/practice-and-results-in-the-investigation-and-management-of-uterine-sarcomas-primus-study/#respond</comments>
		
		<dc:creator><![CDATA[jack]]></dc:creator>
		<pubDate>Wed, 06 May 2026 06:38:22 +0000</pubDate>
				<category><![CDATA[Research]]></category>
		<category><![CDATA[Research & projects]]></category>
		<guid isPermaLink="false">https://lmsrukdev.4pplecore.dev/?p=259</guid>

					<description><![CDATA[<p>Dr Alex Lee (The Christie NHS Foundation, Manchester)</p>
<p>The post <a href="https://lmsruk.org/research-projects/practice-and-results-in-the-investigation-and-management-of-uterine-sarcomas-primus-study/">Practice and Results in the Investigation and Management of Uterine Sarcomas (PRIMUS) Study</a> appeared first on <a href="https://lmsruk.org">Leiomyosarcoma Research UK</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">Uterine sarcomas are rare but aggressive cancers of the womb, with around 250 women diagnosed each year in the UK. One particularly serious type is uterine leiomyosarcoma (LMS). Although uncommon, these cancers can grow and spread quickly, making early and accurate diagnosis vital for improving survival and long-term outcomes.</p>



<p class="wp-block-paragraph">Detecting uterine sarcoma early is extremely challenging. Symptoms such as heavy or irregular periods, pelvic pain, or abdominal swelling are very common and are usually caused by fibroids, which are non-cancerous growths affecting many women. Because fibroids are far more likely, sarcoma is often not suspected, leading to delays in diagnosis and treatment.</p>



<p class="wp-block-paragraph">Current medical tests cannot reliably distinguish benign fibroids from dangerous cancers. Ultrasound and CT scans are usually unable to tell the difference, while MRI scans and biopsies can still be unclear or misleading. This leaves both patients and clinicians making difficult decisions without the certainty they need.</p>



<p class="wp-block-paragraph">As a result, some women undergo surgery that unintentionally delays appropriate cancer treatment or worsens outcomes, while others may have major surgery, including removal of the womb and loss of fertility, only later to discover that their tumour was not cancerous. Care pathways also vary widely across the UK, meaning that where a woman lives can influence the care she receives.</p>



<p class="wp-block-paragraph">To address these challenges, we are supporting Dr Alex Lee&#8217;s two-year research programme (Early Career Fellowship), which focuses on improving how uterine sarcoma, particularly LMS, is identified and managed. The programme will begin by mapping how women with suspected uterine sarcoma are currently diagnosed and treated across the UK, highlighting variation, gaps in care, and opportunities for improvement.</p>



<p class="wp-block-paragraph">The research also includes a pilot study in Greater Manchester, recruiting women with suspicious fibroids or confirmed uterine sarcoma. Participants will receive advanced MRI scans analysed using artificial intelligence, alongside blood tests known as &#8220;liquid biopsies&#8221; that look for traces of cancer DNA in the bloodstream. Tumour samples will also be collected to support future molecular research.</p>



<p class="wp-block-paragraph">Learning from this work will be shared nationally with gynaecological cancer specialists, including close collaboration with Professor Esther Moss at Leicester University Hospital, helping spread best practice and accelerate progress across multiple research projects. Women involved in the study will be followed over time to track outcomes such as recurrence and survival, with patients and families involved throughout. Together, this work aims to improve early detection, reduce unnecessary surgery, and deliver better, fairer care for every woman, wherever she lives.</p>
<p>The post <a href="https://lmsruk.org/research-projects/practice-and-results-in-the-investigation-and-management-of-uterine-sarcomas-primus-study/">Practice and Results in the Investigation and Management of Uterine Sarcomas (PRIMUS) Study</a> appeared first on <a href="https://lmsruk.org">Leiomyosarcoma Research UK</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://lmsruk.org/research-projects/practice-and-results-in-the-investigation-and-management-of-uterine-sarcomas-primus-study/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Regional Engagement Workshops</title>
		<link>https://lmsruk.org/research-projects/regional-engagement-workshops/</link>
					<comments>https://lmsruk.org/research-projects/regional-engagement-workshops/#respond</comments>
		
		<dc:creator><![CDATA[jack]]></dc:creator>
		<pubDate>Wed, 06 May 2026 06:41:09 +0000</pubDate>
				<category><![CDATA[Awareness]]></category>
		<category><![CDATA[Engagement]]></category>
		<category><![CDATA[Research & projects]]></category>
		<guid isPermaLink="false">https://lmsrukdev.4pplecore.dev/?p=268</guid>

					<description><![CDATA[<p>In partnership with Sarcoma UK, we are developing a series of regional engagement workshops that will bring together colleagues from sarcoma centres and local services, including general oncology and gynaecological oncology teams. These workshops will initially be piloted at two to three sites to identify the most effective engagement format. The workshops will provide a [&#8230;]</p>
<p>The post <a href="https://lmsruk.org/research-projects/regional-engagement-workshops/">Regional Engagement Workshops</a> appeared first on <a href="https://lmsruk.org">Leiomyosarcoma Research UK</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">In partnership with Sarcoma UK, we are developing a series of regional engagement workshops that will bring together colleagues from sarcoma centres and local services, including general oncology and gynaecological oncology teams. These workshops will initially be piloted at two to three sites to identify the most effective engagement format.</p>



<p class="wp-block-paragraph">The workshops will provide a forum to share best practice, strengthen collaboration, and explore future research opportunities. This work is informed by the LMS Pathfinder Network (a UK-wide network of sarcoma healthcare professionals) which we continue to coordinate to drive this activity forward. Ultimately, this initiative aims to improve outcomes for patients with uterine sarcoma.</p>



<p class="wp-block-paragraph">Insights from LMS Research UK 2025 workshops, which were co-sponsored by Sarcoma UK, highlighted significant regional variation in research practice and collaboration between sarcoma and gynaecology teams. While some regions demonstrate strong multidisciplinary working, others lack this level of integration. We aim to address these disparities by increasing regional engagement, identifying local challenges, and supporting improved collaborative research practices.</p>



<p class="wp-block-paragraph">This programme aligns with the LMS Pathfinder Network and LMS Research UK&#8217;s broader FOCUS initiative (Finding and Improving Outcomes to Support Uterine Sarcoma), which seeks to strengthen partnerships between gynaecology and sarcoma teams nationwide.</p>
<p>The post <a href="https://lmsruk.org/research-projects/regional-engagement-workshops/">Regional Engagement Workshops</a> appeared first on <a href="https://lmsruk.org">Leiomyosarcoma Research UK</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://lmsruk.org/research-projects/regional-engagement-workshops/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>National (Virtual) Leiomyosarcoma BioBank</title>
		<link>https://lmsruk.org/research-projects/national-virtual-leiomyosarcoma-biobank/</link>
					<comments>https://lmsruk.org/research-projects/national-virtual-leiomyosarcoma-biobank/#respond</comments>
		
		<dc:creator><![CDATA[jack]]></dc:creator>
		<pubDate>Wed, 06 May 2026 06:40:50 +0000</pubDate>
				<category><![CDATA[Research]]></category>
		<category><![CDATA[Research & projects]]></category>
		<guid isPermaLink="false">https://lmsrukdev.4pplecore.dev/?p=266</guid>

					<description><![CDATA[<p>We are beginning the planning and development of a National (virtual) Leiomyosarcoma (LMS) biobank encompassing tissue, blood, and associated data. This is a major initiative designed to support LMS research by significantly improving researchers&#8217; access to high-quality samples and data, which is an area currently recognised as a major barrier to progress in LMS research. [&#8230;]</p>
<p>The post <a href="https://lmsruk.org/research-projects/national-virtual-leiomyosarcoma-biobank/">National (Virtual) Leiomyosarcoma BioBank</a> appeared first on <a href="https://lmsruk.org">Leiomyosarcoma Research UK</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">We are beginning the planning and development of a National (virtual) Leiomyosarcoma (LMS) biobank encompassing tissue, blood, and associated data. This is a major initiative designed to support LMS research by significantly improving researchers&#8217; access to high-quality samples and data, which is an area currently recognised as a major barrier to progress in LMS research. The biobank is intended to include all LMS subtypes.</p>



<p class="wp-block-paragraph">Alongside this, we are working closely with sarcoma researchers to develop targeted research proposals that will make use of the LMS Biobank. These projects will support ongoing research and innovation, with the ultimate aim of improving outcomes for people living with leiomyosarcoma.</p>
<p>The post <a href="https://lmsruk.org/research-projects/national-virtual-leiomyosarcoma-biobank/">National (Virtual) Leiomyosarcoma BioBank</a> appeared first on <a href="https://lmsruk.org">Leiomyosarcoma Research UK</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://lmsruk.org/research-projects/national-virtual-leiomyosarcoma-biobank/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Leiomyosarcoma Awareness Campaign</title>
		<link>https://lmsruk.org/research-projects/leiomyosarcoma-awareness-campaign/</link>
					<comments>https://lmsruk.org/research-projects/leiomyosarcoma-awareness-campaign/#respond</comments>
		
		<dc:creator><![CDATA[jack]]></dc:creator>
		<pubDate>Wed, 06 May 2026 06:41:28 +0000</pubDate>
				<category><![CDATA[Awareness]]></category>
		<category><![CDATA[Research & projects]]></category>
		<guid isPermaLink="false">https://lmsrukdev.4pplecore.dev/?p=270</guid>

					<description><![CDATA[<p>Leiomyosarcoma remains poorly recognised both within the UK and internationally, among the general public and healthcare professionals. We are therefore in the early stages of developing a national awareness campaign focused on leiomyosarcoma and its subtypes. The campaign will actively involve patients, including sharing individual case studies to support learning, build understanding, and increase overall [&#8230;]</p>
<p>The post <a href="https://lmsruk.org/research-projects/leiomyosarcoma-awareness-campaign/">Leiomyosarcoma Awareness Campaign</a> appeared first on <a href="https://lmsruk.org">Leiomyosarcoma Research UK</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">Leiomyosarcoma remains poorly recognised both within the UK and internationally, among the general public and healthcare professionals. We are therefore in the early stages of developing a national awareness campaign focused on leiomyosarcoma and its subtypes.</p>



<p class="wp-block-paragraph">The campaign will actively involve patients, including sharing individual case studies to support learning, build understanding, and increase overall awareness of the disease among key stakeholder groups.</p>
<p>The post <a href="https://lmsruk.org/research-projects/leiomyosarcoma-awareness-campaign/">Leiomyosarcoma Awareness Campaign</a> appeared first on <a href="https://lmsruk.org">Leiomyosarcoma Research UK</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://lmsruk.org/research-projects/leiomyosarcoma-awareness-campaign/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>FOCUS programme (Finding and Improving Outcomes to Support Uterine Sarcoma)</title>
		<link>https://lmsruk.org/research-projects/focus-programme-finding-and-improving-outcomes-to-support-uterine-sarcoma/</link>
					<comments>https://lmsruk.org/research-projects/focus-programme-finding-and-improving-outcomes-to-support-uterine-sarcoma/#respond</comments>
		
		<dc:creator><![CDATA[jack]]></dc:creator>
		<pubDate>Wed, 13 May 2026 06:41:33 +0000</pubDate>
				<category><![CDATA[Engagement]]></category>
		<category><![CDATA[Research]]></category>
		<category><![CDATA[Research & projects]]></category>
		<guid isPermaLink="false">https://lmsrukdev.4pplecore.dev/?p=291</guid>

					<description><![CDATA[<p>The FOCUS programme was created and developed by the LMS Pathfinder Network. The programme deliberately concentrates on uterine sarcoma, with a particular focus on uterine leiomyosarcoma. This focus was chosen to enable the development of a cohesive, integrated programme that brings together clinical and biological approaches to improve outcomes for patients with uterine leiomyosarcoma, while [&#8230;]</p>
<p>The post <a href="https://lmsruk.org/research-projects/focus-programme-finding-and-improving-outcomes-to-support-uterine-sarcoma/">FOCUS programme (Finding and Improving Outcomes to Support Uterine Sarcoma)</a> appeared first on <a href="https://lmsruk.org">Leiomyosarcoma Research UK</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">The FOCUS programme was created and developed by the LMS Pathfinder Network. The programme deliberately concentrates on uterine sarcoma, with a particular focus on uterine leiomyosarcoma. This focus was chosen to enable the development of a cohesive, integrated programme that brings together clinical and biological approaches to improve outcomes for patients with uterine leiomyosarcoma, while also identifying insights and strategies that may be applicable to other leiomyosarcoma subtypes.</p>



<p class="wp-block-paragraph">The programme provides a framework for exploring genomics, proteomics, transcriptomics, and immune microenvironment research, enabling robust multidisciplinary collaboration. A schematic overview of the FOCUS programme illustrates its structure and highlights the opportunities it creates for cross-disciplinary working.</p>



<p class="wp-block-paragraph">Current projects supported by Leiomyosarcoma Research UK feed directly into the FOCUS programme, helping to drive forward this coordinated programme of research and innovation.</p>
<p>The post <a href="https://lmsruk.org/research-projects/focus-programme-finding-and-improving-outcomes-to-support-uterine-sarcoma/">FOCUS programme (Finding and Improving Outcomes to Support Uterine Sarcoma)</a> appeared first on <a href="https://lmsruk.org">Leiomyosarcoma Research UK</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://lmsruk.org/research-projects/focus-programme-finding-and-improving-outcomes-to-support-uterine-sarcoma/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Latest Leiomyosarcoma Research Updates from Our Pathfinder Meeting</title>
		<link>https://lmsruk.org/news/lms-research-uk/leiomyosarcoma-research-pathfinder-update/</link>
					<comments>https://lmsruk.org/news/lms-research-uk/leiomyosarcoma-research-pathfinder-update/#respond</comments>
		
		<dc:creator><![CDATA[Leo Casimo]]></dc:creator>
		<pubDate>Mon, 02 Nov 2026 08:58:08 +0000</pubDate>
				<category><![CDATA[LMS Research UK]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Research & projects]]></category>
		<category><![CDATA[Biomarkers]]></category>
		<category><![CDATA[Cancer Research]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Leiomyosarcoma]]></category>
		<category><![CDATA[LMS Pathfinder Network]]></category>
		<category><![CDATA[Uterine Leiomyosarcoma]]></category>
		<guid isPermaLink="false">https://lmsruk.org/?p=471</guid>

					<description><![CDATA[<p>Researchers, clinicians and LMS Research UK representatives came together for the latest Pathfinder meeting to share updates on leiomyosarcoma research, clinical trials and opportunities for greater collaboration across the UK.</p>
<p>The post <a href="https://lmsruk.org/news/lms-research-uk/leiomyosarcoma-research-pathfinder-update/">Latest Leiomyosarcoma Research Updates from Our Pathfinder Meeting</a> appeared first on <a href="https://lmsruk.org">Leiomyosarcoma Research UK</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph"><span style="font-family: &quot;Times New Roman&quot;, serif; white-space: normal;">Researchers, clinicians and LMS Research UK trustees and volunteers came together online this summer for an <a href="https://lmsruk.org/research-projects/leiomyosarcoma-lms-pathfinder-network/">LMS Pathfinder Networking</a> meeting to share updates on uterine leiomyosarcoma research and discuss opportunities to work more closely together.</span></p>



<h2 class="wp-block-heading"><span style="font-size: 18pt; font-family: &quot;Times New Roman&quot;, serif;"><strong>Dr Alexander Lee: The PRIMUS study</strong></span></h2>



<p class="wp-block-paragraph">Dr Alexander Lee presented the newly funded PRIMUS study, which aims to build a clearer picture of how uterine sarcoma is diagnosed and managed across the UK.</p>



<p class="wp-block-paragraph">The programme will map current clinical pathways and establish a prospective patient cohort. It will also collect blood, imaging and tissue samples for biomarker research, with the aim of supporting future studies involving circulating tumour DNA (ctDNA) and AI-enabled imaging. Patient involvement will help shape future research priorities.</p>



<h2 class="wp-block-heading"><p class="MsoNormal" style="margin: 0cm; font-size: medium; font-family: Aptos, sans-serif; white-space: normal;"><b><span style="font-size: 18pt; font-family: &quot;Times New Roman&quot;, serif;">Professor Esther Moss: Updates on the DOORS-D and DOORS-M studies</span></b></p></h2>



<p class="wp-block-paragraph">Professor Esther Moss shared updates on the DOORS-D and DOORS-M studies, which are exploring blood-based biomarkers, ctDNA monitoring, imaging, digital pathology and radiomics.</p>



<p class="wp-block-paragraph">Recruitment is expanding across several UK centres, with international collaboration helping to strengthen data and sample collection. Qualitative research is also exploring people’s experiences and diagnostic journeys.</p>



<p class="wp-block-paragraph">Both research teams discussed ways to align protocols, share learning and validate findings across independent patient cohorts. This collaboration can help build the evidence needed to assess how research findings may be used in future clinical practice.</p>



<h2 class="wp-block-heading"><p class="MsoNormal" style="margin: 0cm; font-size: medium; font-family: Aptos, sans-serif; white-space: normal;"><b><span style="font-size: 18pt; font-family: &quot;Times New Roman&quot;, serif;">Professor Robin Jones: Leiomyosarcoma clinical trial update</span></b></p></h2>



<p class="wp-block-paragraph">Professor Robin Jones reviewed ongoing and recently completed studies in leiomyosarcoma. These included an international trial comparing adjuvant chemotherapy after surgery with surveillance only for people with high-risk uterine LMS disease.</p>



<p class="wp-block-paragraph">He also discussed results from a phase III study in advanced leiomyosarcoma, which showed an improvement in progression-free survival and highlighted the continuing need for predictive biomarkers. Recruitment has also been completed for a phase III trial comparing doxorubicin with doxorubicin plus lurbinectedin in metastatic leiomyosarcoma; results are awaited.</p>



<h2 class="wp-block-heading"><p class="MsoNormal" style="margin: 0cm; font-size: medium; font-family: Aptos, sans-serif; white-space: normal;"><b><span style="font-size: 18pt; font-family: &quot;Times New Roman&quot;, serif;">Building collaboration across the UK</span></b></p></h2>



<p class="wp-block-paragraph">The meeting highlighted growing activity in leiomyosarcoma research, including work on diagnosis, biomarkers and clinical trials. Participants discussed how closer collaboration could help researchers share knowledge and strengthen future studies.</p>



<p class="wp-block-paragraph">Our priorities include developing regional workshops, exploring a national virtual uterine sarcoma tissue bank, identifying infrastructure needs for future collaborative funding applications, and continuing to raise awareness of leiomyosarcoma. Patient-facing research webinars are also being considered.</p>



<p class="wp-block-paragraph">We thank all the presenters and participants for sharing their work and contributing to the discussion.</p>


<div class="wp-block-image">
<figure class="aligncenter size-large"><img fetchpriority="high" decoding="async" width="1024" height="531" src="https://lmsruk.org/wp-content/uploads/2026/11/workshops-1024x531.png" alt="" class="wp-image-473" style="aspect-ratio:1.928540680154972" srcset="https://lmsruk.org/wp-content/uploads/2026/11/workshops-1024x531.png 1024w, https://lmsruk.org/wp-content/uploads/2026/11/workshops-300x156.png 300w, https://lmsruk.org/wp-content/uploads/2026/11/workshops-768x398.png 768w, https://lmsruk.org/wp-content/uploads/2026/11/workshops.png 1199w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
</div><p>The post <a href="https://lmsruk.org/news/lms-research-uk/leiomyosarcoma-research-pathfinder-update/">Latest Leiomyosarcoma Research Updates from Our Pathfinder Meeting</a> appeared first on <a href="https://lmsruk.org">Leiomyosarcoma Research UK</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://lmsruk.org/news/lms-research-uk/leiomyosarcoma-research-pathfinder-update/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
	</channel>
</rss>
